

**Table 1: TR02 Mean Reduction in Worst itch NRS During the Evaluation Period (MITT Population)**

Mean (SD) NRS <sup>†</sup> Data	<b>NAL 60</b>	<b>NAL 120</b>	<b>Placebo</b>
N (number of patients)	128	120	123
<b>Baseline</b>	N=128 6.87 (1.40)	N=120 6.94 (1.46)	N=123 6.75 (1.37)
<b>Evaluation Period (Observed Cases)</b>	N=82 3.97 (2.52)	N=84 3.51 (2.11)	N=108 4.03 (2.48)
<b>Change from Baseline</b>	-3.10 (2.35)	-3.49 (2.37)	-2.80 (2.22)
<b>LS Mean Difference from Placebo</b>	-0.24	-0.73	
<b>p-value vs Placebo</b>	0.432	0.017*	

\*statistical significance defined per protocol as p-value  $\leq 0.05$  based step-down analysis specification; initial comparison of NAL 120 vs. placebo based on least square (LS) means  
Modified Intent-to-Treat Population